Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA’s Promotional Enforcement Still Playing It Safe

Executive Summary

Even with letter citing Spanish video for Oxtellar seizure, US regulatory agency likely to issue record low number of letters this year.

You may also be interested in...



Keeping Track: Vitaros Reenters The Wilderness, Remoxy Gives It A Fourth Try, And Two Novel Approvals

The latest drug development news and highlights from our US FDA Performance Tracker.

Opioid Warning Letter To Cipher Likely Easy Call For US FDA

Murky enforcement environment has probably contributed to FDA's record-low number of letters, but detailing material for ConZip failed to include risk information and important limitations of use for the tramadol extended-release product.

FDA’s Rx Promo Citations Rise Slightly In 2016; Investigational Drug Promos Scrutinized

Office of Prescription Drug Promotion seemed to expand its focus in issuing 11 letters last year.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

PS119464

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel